Shots: The approval is based on ENSEMBLE PLUS study, which demonstrated similar frequency and severity of IRRs for 2hrs. Ocrevus infusion time vs conventional 3.5hrs in patients with RRMS. The initial dose is given as two 300mg infusions given 2wks. apart and a subsequent dose of single 600mg infusions were administered over a shorter, 2hrs. […]Read More
Shots: The approval is based on ENSEMBLE PLUS study, which demonstrated comparable frequency and severity of IRRs for 2hrs. OCREVUS infusion time (dosed twice yearly) vs conventional 3.5hrs in patients with RRMS. The initial dose is given as two 300mg infusions given 2wks. apart and a subsequent dose single 600mg infusions were administered over a […]Read More
Shots: The P-III OPERA, ORATORIO and OBOE studies result involves assessing of Ocrevus (ocrelizumab) vs PBO in patients with RMS and PPMS, presented at AAN Annual Meeting Results: reduction in risk of disability progression associated with exposure and lower B-cell levels & permanent disability progression; @24wks. reduction in CDP; @48wks. RMS, PPMS patients with CDP […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
